Disseminated intravascular coagulation Prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(3 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{DIC}}
{{DIC}}
{{CMG}}
{{CMG}};{{AE}} {{OK}}


==Overview==
==Overview==
There are no established measures for the primary prevention of [disease name].
There are no established measures for the prevention of [[DIC]]. The threshold of initiation of prevention therapy for [[bleeding]] in [[DIC]] is a [[platelet count]] of ≥10,000/microL. Some studies suggest a [[platelet]] count of 20,000/microL without [[bleeding]]. There is little evidence to support [[Preventive care|preventive]] measures for [[thrombosis]] in [[DIC]].  
 
OR
 
There are no available vaccines against [disease name].
 
OR
 
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
 
OR
 
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
 
==Primary Prevention==
There are no established measures for the primary prevention of [disease name].
 
OR
 
There are no available vaccines against [disease name].
 
OR
 
Effective measures for the primary prevention of [disease name] include:
*[Measure1]
*[Measure2]
*[Measure3]
 
OR
 
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
*[Strategy 1]
*[Strategy 2]
*[Strategy 3]


==Prevention==
There are no established measures for the prevention of [[DIC]]. The threshold of initiation of prevention therapy for [[bleeding]] in [[DIC]] is a [[platelet count]] of ≥10,000/microL. Some studies suggest a [[platelet count]] of 20,000/microL without [[bleeding]].<ref name="pmid26676927">{{cite journal |vauthors=Squizzato A, Hunt BJ, Kinasewitz GT, Wada H, Ten Cate H, Thachil J, Levi M, Vicente V, D'Angelo A, Di Nisio M |title=Supportive management strategies for disseminated intravascular coagulation. An international consensus |journal=Thromb. Haemost. |volume=115 |issue=5 |pages=896–904 |date=May 2016 |pmid=26676927 |doi=10.1160/TH15-09-0740 |url=}}</ref> There is little evidence to support preventive measures for [[thrombosis]] in [[DIC]]. Some experts maintain a fibrinogen level above 100 mg/dl in order to prevent complications of DIC. This can be achieved via transfusion of cryoprecipitate.


==References==
==References==

Latest revision as of 03:16, 24 December 2018

Disseminated intravascular coagulation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Disseminated intravascular coagulation from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Disseminated intravascular coagulation Prevention On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Disseminated intravascular coagulation Prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Disseminated intravascular coagulation Prevention

CDC on Disseminated intravascular coagulation Prevention

Disseminated intravascular coagulation Prevention in the news

Blogs on Disseminated intravascular coagulation Prevention

Directions to Hospitals Treating Disseminated intravascular coagulation

Risk calculators and risk factors for Disseminated intravascular coagulation Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]

Overview

There are no established measures for the prevention of DIC. The threshold of initiation of prevention therapy for bleeding in DIC is a platelet count of ≥10,000/microL. Some studies suggest a platelet count of 20,000/microL without bleeding. There is little evidence to support preventive measures for thrombosis in DIC.

Prevention

There are no established measures for the prevention of DIC. The threshold of initiation of prevention therapy for bleeding in DIC is a platelet count of ≥10,000/microL. Some studies suggest a platelet count of 20,000/microL without bleeding.[1] There is little evidence to support preventive measures for thrombosis in DIC. Some experts maintain a fibrinogen level above 100 mg/dl in order to prevent complications of DIC. This can be achieved via transfusion of cryoprecipitate.

References

  1. Squizzato A, Hunt BJ, Kinasewitz GT, Wada H, Ten Cate H, Thachil J, Levi M, Vicente V, D'Angelo A, Di Nisio M (May 2016). "Supportive management strategies for disseminated intravascular coagulation. An international consensus". Thromb. Haemost. 115 (5): 896–904. doi:10.1160/TH15-09-0740. PMID 26676927.


Template:WS Template:WH